Zymeworks Inc.
Close on Oct 19, 2026
- Market cap
- $1.86B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 6, 2026 | After market close | $4.60M | $-0.62 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | After market close | $2.40M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Jan 12, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | After market close | $27.60M | $-0.26 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | After market close | $48.70M | $0.03 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | After market close | $27.10M | $-0.30 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Jan 8, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 31, 2024 | After market close | $16.00M | $-0.39 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 1, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 2, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 6, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on May 7, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| adjusted gross operating expenses (non-GAAP)non-GAAP | 2026 | -20% growth | New |
| aggregate adjusted gross operating expenditures (non-GAAP)non-GAAP | three-year period ending December 31, 2028 | $300.00M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Zymeworks filed with the SEC
Zymeworks Completes Acquisition of Theravance Biopharma
Material agreement · Acquisition or disposition completed · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Zymeworks Provides Corporate Update and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Zymeworks to Acquire Theravance Biopharma, Inc.
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
to Acquire Theravance Biopharma June 29, 2026 Transaction delivers high-visibility, long-duration recurring cash flows Exhibit 99.2
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Zymeworks Provides Corporate Update and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
Material agreement · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
Zymeworks Provides Corporate Update and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Zymeworks Outlines Strategic Priorities and Outlook for 2026
Results of operations · Executive or director change · Other events · EX-99.1 to Form 8-K
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy
Results of operations · Executive or director change · Other events · EX-99.2 to Form 8-K
Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by
Executive or director change · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer
Executive or director change · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
HERIZON-GEA-01 Phase 3 Results Supporting Ziihera ®
Other events · EX-99.1 to Form 8-K
Zymeworks Provides Corporate Update and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry
Material agreement · Unregistered share sale · Executive or director change · Other events · EX-99.1 to Form 8-K
Zymeworks Provides Corporate Update and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated,
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Zymeworks Provides Corporate Update and
Results of operations · Regulation FD disclosure · EX-99 to Form 8-K
Zymeworks Provides Corporate Update and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors
Executive or director change · Other events · EX-99.1 to Form 8-K
Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026
Results of operations · Other events · EX-99.1 to Form 8-K
FDA Grants U.S. Approval of Ziihera ®
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Zymeworks Provides Corporate Update and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Zymeworks Provides Corporate Update and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Zymeworks Provides Corporate Update and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
Executive or director change · Other events · EX-99.1 to Form 8-K
Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors
Executive or director change · Other events · EX-99.1 to Form 8-K
Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025
Results of operations · Other events · EX-99 to Form 8-K
Zymeworks Announces $50 Million Private Placement to EcoR1 Capital
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Zymeworks Provides Corporate Update and
Results of operations · EX-99.1 to Form 8-K
Zymeworks Announces New Director Nominee
Executive or director change · Other events · EX-99.1 to Form 8-K
Zymeworks Provides Corporate Update and
Results of operations · EX-99.1 to Form 8-K
Vancouver, British Columbia (June 29, 2023) – Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel,
Executive or director change · Other events · EX-99.1 to Form 8-K
Zymeworks Provides Corporate Update and
Results of operations · EX-99.1 to Form 8-K
Zymeworks Presents New Data from Multiple Preclinical and Clinical Development Programs at the 2023
Other events · EX-99.1 to Form 8-K
Zymeworks Reports Fourth Quarter and Full Year 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K